Physician profile
Peter Edenhoffer
NPI 1790898963
$3,107.01
in general payments reported to CMS, 2019-2025
30 companies · $749 in 2025
The $749 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,384 · 2020: $274 · 2022: $120 · 2023: $187 · 2024: $392 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $601.26 | 2019 | |
| Medtronic, INC. | $366.09 | 2023-2024 | Intellis Adaptivestim |
| Emd Serono, INC. | $285.68 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $228.66 | 2019 | |
| Spr Therapeutics, INC | $160.78 | 2019-2022 | |
| Tg Therapeutics, INC. | $126.93 | 2025 | |
| Argenx US, INC. | $125.00 | 2025 | Vyvgart Hytrulo |
| Eisai INC. | $124.99 | 2024 | |
| Corcept Therapeutics | $124.98 | 2025 | Korlym |
| Amgen INC. | $124.92 | 2025 | Evenity |
| Axsome Therapeutics, INC. | $121.79 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $108.16 | 2019 | |
| Glaxosmithkline, LLC. | $107.82 | 2025 | Shingrix |
| Abbvie INC. | $78.27 | 2022-2024 | |
| Greenwich Biosciences, INC. | $62.95 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $48.88 | 2019 | |
| Lilly USA, LLC | $47.81 | 2019 | |
| Allergan, INC. | $33.78 | 2019-2020 | |
| Medtronic USA, INC. | $32.56 | 2020 | |
| Ucb, INC. | $25.95 | 2019 | |
| Adamas Pharmaceuticals, INC. | $25.90 | 2019 | |
| Tanabe Pharma America, INC. | $21.55 | 2024 | |
| Lundbeck LLC | $17.77 | 2019 | |
| Livanova USA, INC. | $17.50 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.29 | 2025 | Edarbi |
| Nevro Corp. | $16.55 | 2024 | Senza |
| Radius Health, INC. | $15.38 | 2019 | |
| Mdd US Operations, LLC | $14.76 | 2022 | |
| Jazz Pharmaceuticals INC. | $11.81 | 2022 | |
| Biogen, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Edenhoffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.